Private imaging facilitiesgrew at hospitals' expense
Use of noninvasive diagnostic imaging at private imaging facilities between 1996 and 2006 skyrocketed while hospitals' share of the imaging market fell, according to a Thomas Jefferson University study.
Use of noninvasive diagnostic imaging at private imaging facilities between 1996 and 2006 skyrocketed while hospitals' share of the imaging market fell, according to a Thomas Jefferson University study. Findings suggest hospitals failed to adjust to a booming imaging market. Dr. David C. Levin and colleagues examined nationwide Medicare Part B databases from 1996 to 2006 comparing noninvasive diagnostic imaging codes with place-of-service codes. They found NDI utilization rates per 1000 patients increased at all four places of service: hospital inpatient, hospital outpatient, private office, and emergency department. While hospital outpatient facilities and private offices saw increases of 25% and 63%, respectively, the rate for hospital inpatients grew only 15%. ER utilization rates were lower than in the other places, but their growth was fastest at 77% (J Am Coll Radiol 2009;6:96-99).
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
